Trial Profile
Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2012
Price :
$35
*
At a glance
- Drugs MK 5046 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 09 Jan 2012 New trial record
- 12 Dec 2011 Results published in the Journal of Clinical Pharmacology.